Kura Oncology (NASDAQ:KURA) Given New $16.00 Price Target at UBS Group

Kura Oncology (NASDAQ:KURA) had its price objective raised by equities research analysts at UBS Group from $14.00 to $16.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s price objective would suggest a potential upside of 32.29% from the stock’s current price.

A number of other research analysts also recently commented on the stock. Guggenheim initiated coverage on shares of Kura Oncology in a research report on Thursday, September 4th. They issued a “neutral” rating for the company. Wedbush reiterated an “outperform” rating and set a $38.00 price target (up previously from $36.00) on shares of Kura Oncology in a report on Friday. Zacks Research upgraded Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a research note on Wednesday, October 8th. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Kura Oncology in a research note on Friday. Ten investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.11.

Kura Oncology Stock Up 13.2%

Shares of NASDAQ:KURA traded up $1.42 during trading on Friday, hitting $12.10. 3,184,938 shares of the company were exchanged, compared to its average volume of 1,583,286. Kura Oncology has a fifty-two week low of $5.41 and a fifty-two week high of $16.68. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -4.88 and a beta of 0.35. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 0.02. The firm has a fifty day moving average price of $9.40 and a two-hundred day moving average price of $7.44.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Tuesday, November 4th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.28). The firm had revenue of $20.75 million during the quarter, compared to the consensus estimate of $17.48 million. Kura Oncology had a negative net margin of 208.48% and a negative return on equity of 65.42%. As a group, research analysts anticipate that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Insider Activity at Kura Oncology

In other Kura Oncology news, SVP Thomas James Doyle sold 4,541 shares of Kura Oncology stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $8.94, for a total value of $40,596.54. Following the completion of the sale, the senior vice president owned 109,829 shares in the company, valued at $981,871.26. The trade was a 3.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Teresa Brophy Bair sold 8,805 shares of the stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $8.94, for a total transaction of $78,716.70. Following the transaction, the insider owned 148,043 shares in the company, valued at approximately $1,323,504.42. The trade was a 5.61% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 78,058 shares of company stock valued at $697,839. 6.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Kura Oncology

A number of large investors have recently added to or reduced their stakes in the stock. Jacobs Levy Equity Management Inc. raised its stake in Kura Oncology by 57.9% in the first quarter. Jacobs Levy Equity Management Inc. now owns 1,544,113 shares of the company’s stock valued at $10,191,000 after purchasing an additional 566,193 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in Kura Oncology by 169.3% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 56,912 shares of the company’s stock valued at $334,000 after buying an additional 35,779 shares during the period. Hsbc Holdings PLC raised its position in shares of Kura Oncology by 26.5% in the 1st quarter. Hsbc Holdings PLC now owns 54,491 shares of the company’s stock valued at $351,000 after buying an additional 11,406 shares in the last quarter. Acadian Asset Management LLC bought a new stake in shares of Kura Oncology during the 1st quarter worth approximately $2,180,000. Finally, AQR Capital Management LLC lifted its holdings in shares of Kura Oncology by 407.8% during the 1st quarter. AQR Capital Management LLC now owns 760,332 shares of the company’s stock worth $5,018,000 after acquiring an additional 610,604 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.